VXA-G1.1-NN + VXA-G2.4-NS for caliciviridae infections

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 Mar 2019: Trial started, NCT03897309
  2. 1 Apr 2019: Trial registered, NCT03897309

The trials

NCT03897309: Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines

State
Completed
Phase
Phase 1
People
86 taking part
Started
20 Mar 2019
Primary completion
15 Jan 2021
Arms
Bivalent GI.1 and GII.4 vaccine group
Results
None posted
  1. 20 Mar 2019: Trial started
  2. 1 Apr 2019: Trial registered
  3. 1 Apr 2021: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.